三生国健：重组抗IL-1β人源化单克隆抗体注射液新药上市申请获受理

Core Viewpoint - Sanofi's application for the new drug SSGJ-613, a recombinant humanized monoclonal antibody targeting IL-1β for acute gouty arthritis, has been accepted by the National Medical Products Administration after achieving primary efficacy endpoints in Phase III clinical trials [1] Group 1 - The drug SSGJ-613 is developed independently by the company and represents a novel anti-IL-1β antibody with a completely different binding epitope compared to existing products on the market targeting the same pathway [1]